Mineralys Therapeutics (MLYS) to Release Earnings on Tuesday

Key Points

• Mineralys Therapeutics is set to release its Q2 2025 earnings on August 12th, where analysts anticipate a loss of ($0.78) per share.
• Despite a recent increase in stock price by 3.2%, the current market cap of Mineralys Therapeutics stands at approximately $876.35 million.
• Several analysts have varied ratings on the stock, with a consensus target price of $32.25, indicating mixed outlooks among investors.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.23. On average, analysts expect Mineralys Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Mineralys Therapeutics Trading Up 1.0%

Shares of NASDAQ:MLYS traded up $0.13 during trading on Friday, hitting $13.00. 502,001 shares of the company's stock were exchanged, compared to its average volume of 693,613. Mineralys Therapeutics has a 1-year low of $8.24 and a 1-year high of $18.38. The firm has a 50-day moving average price of $14.25 and a two-hundred day moving average price of $13.42. The firm has a market cap of $847.34 million, a P/E ratio of -3.49 and a beta of -0.29.

Insider Activity

In other news, CFO Adam Scott Levy sold 59,925 shares of the company's stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $14.76, for a total value of $884,493.00. Following the completion of the transaction, the chief financial officer owned 132,934 shares in the company, valued at $1,962,105.84. This represents a 31.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jon Congleton sold 15,884 shares of the business's stock in a transaction on Friday, July 11th. The stock was sold at an average price of $14.51, for a total transaction of $230,476.84. Following the completion of the sale, the chief executive officer directly owned 846,405 shares in the company, valued at approximately $12,281,336.55. This represents a 1.84% decrease in their position. The disclosure for this sale can be found here. Insiders sold 123,052 shares of company stock worth $1,803,099 over the last quarter. 25.56% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

Several large investors have recently modified their holdings of MLYS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Mineralys Therapeutics by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company's stock valued at $271,000 after acquiring an additional 702 shares in the last quarter. Creative Planning acquired a new position in shares of Mineralys Therapeutics in the second quarter valued at about $336,000. AQR Capital Management LLC acquired a new position in shares of Mineralys Therapeutics in the first quarter valued at about $550,000. Woodline Partners LP acquired a new position in shares of Mineralys Therapeutics in the first quarter valued at about $757,000. Finally, Goldman Sachs Group Inc. grew its stake in shares of Mineralys Therapeutics by 166.6% in the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company's stock valued at $4,739,000 after acquiring an additional 186,480 shares in the last quarter. 84.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MLYS has been the subject of a number of analyst reports. Guggenheim set a $48.00 price objective on shares of Mineralys Therapeutics and gave the company a "buy" rating in a report on Wednesday, May 14th. Wall Street Zen cut shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. HC Wainwright restated a "buy" rating and set a $42.00 price objective on shares of Mineralys Therapeutics in a report on Tuesday, June 17th. Finally, Jefferies Financial Group initiated coverage on shares of Mineralys Therapeutics in a report on Tuesday, June 10th. They set a "hold" rating and a $15.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $32.25.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.